Get my own profile
Public access
View all10 articles
1 article
available
not available
Based on funding mandates
Co-authors
- Peter GreasleyEarly Clinical Development, AstraZenecaVerified email at astrazeneca.com
- Sidney AuerbachRutgers UniversityVerified email at biology.rutgers.edu
- Cecilia WikellTeam Leader/Associate Principal Scientist, RIA iMed, AstraZenecaVerified email at astrazeneca.com
- Johanna Andersson-AssarssonSahlgrenska Academy at University of GothenburgVerified email at medic.gu.se
- Markku PeltonenProfessor, National Institute for Health and Welfare (THL), FinlandVerified email at thl.fi
- Tomas DrmotaCONTIPROVerified email at contipro.com
- Nils-Olov HermanssonAstraZenecaVerified email at ekompetens.se
- Viveka HillegaartDocent i Zoologi,SLUVerified email at slu.se
- Per-Arne SvenssonPerfessor in Medical ScienceVerified email at medic.gu.se
- Bo SöderpalmAddiction Biology Unit, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, UniversityVerified email at neuro.gu.se
- Hans NissbrandtProfessor, Dept of Pharmacology, Univ of GothenburgVerified email at gu.se
- Stephane MilanoDirector Preclinical & PharmacologyVerified email at alz-pharma.com
- Kajsa SjöholmAssociate Professor, Gothenburg UniversityVerified email at medic.gu.se
- Annika ÅstrandRIA iMed, AstraZenecaVerified email at astrazeneca.com
- Alonso FernándezProfesor titular, Departamento de Farmacobiologia, Cinvestav Sede SurVerified email at cinvestav.mx
- Mohammad Bohlooly-YExecutive Director AstraZenecaVerified email at astrazeneca.com
- Erik SundströmSenior Researcher, Karolinska InstitutetVerified email at ki.se
- Vicente Martínez PereaProfessor of Physiology, Universitat Autònoma de BarcelonaVerified email at uab.es
- Richard McQuadeVerified email at ncl.ac.uk
- Göran EngbergProfessor of PharmacologyVerified email at ki.se